Maxim analyst Naz Rahman upgraded Agile Therapeutics to Buy from Hold with a $5 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AGRX:
- Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Agile Therapeutics sees 2023 net revenue $25M-$30M
- Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Agile Therapeutics reports Q2 adjusted EPS ($3.10) vs. ($135.46) last year
- AGRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?